Kira Biotech Raises A$20M in Series A Funding

Kira Biotech完成2000万澳元融资,开发难治性免疫系统疾病的新疗法

2019-11-08 11:14:10 Finsmes

本文共379个字,阅读需1分钟

Kira Biotech, a Brisbane, Australia-based immunology company, secured A$20m in Series A funding. The round was led by OneVentures, IP Group and the Advance Queensland Business Development Fund. The company intencds to use the funds to advance its lead candidate KB312 through phase 1 human studies. Led by Dr Dan Baker, founding CEO, Kira Biotech is a biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders, such as rheumatoid arthritis, systemic lupus erythematosus and type 1 diabete. KB312 is an antibody with a novel target that is common to many immune system disorders and is key to restoration or induction of immune tolerance. The company is progressing KB312 through preclinical development and phase 1 clinical trials with a team of drug development experts led by Dr Baker. The research program is based on decades of research led by the late Professor Derek Hart and Associate Professor Georgina Clark. FinSMEs 31/10/2019
总部位于澳大利亚布里斯班的免疫学公司 KiraBiotech 获得了2000万澳元的 A 系列资金。 这轮融资由 OneVentures 、 IP Group 和昆士兰商业发展基金牵头。 该公司打算利用这笔资金通过第一阶段的人类研究来推进其主要候选人 KB312。 在创始人兼首席执行官 DanBaker 博士的带领下, Kira Biotech 是一家生物技术公司,开发新型免疫调节化合物,用于治疗风湿性关节炎、系统性红斑狼疮和1型糖尿病等免疫系统疾病。 KB312是一种抗体,具有许多免疫系统疾病常见的新靶点,是恢复或诱导免疫耐受的关键。公司正在通过临床前开发和1期临床试验,与贝克博士领导的药物开发专家团队共同推进 KB312的进展。 该研究计划基于由已故的德里克·哈特教授和乔治娜·克拉克副教授领导的几十年的研究。 FinSME 31/10/2019

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文